Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Combining two multiple sclerosis treatments has no clinical benefit, study finds.

Anekwe L.

BMJ. 2013 Mar 14;346:f1719. doi: 10.1136/bmj.f1719. No abstract available.

PMID:
23491460
[PubMed - indexed for MEDLINE]
2.

Editorial: the pitfalls of combination therapy.

Vermersch P.

Int MS J. 2006 Nov;13(3):75-6. No abstract available.

PMID:
17101074
[PubMed - indexed for MEDLINE]
3.

[Pharmacological treatment of multiple sclerosis].

Myhr KM.

Tidsskr Nor Laegeforen. 2010 Mar 11;130(5):490-2. doi: 10.4045/tidsskr.09.1126. Norwegian.

PMID:
20224616
[PubMed - indexed for MEDLINE]
Free Article
4.

Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.

Banwell B, Tremlett H.

Neurology. 2005 Mar 8;64(5):778-9. No abstract available.

PMID:
15753408
[PubMed - indexed for MEDLINE]
5.

Multiple sclerosis: monotherapy rules.

Hauser SL, Josephson SA, Johnston SC.

Ann Neurol. 2013 Mar;73(3):A5-6. doi: 10.1002/ana.23886. No abstract available.

PMID:
23596013
[PubMed - indexed for MEDLINE]
6.

Consensus statement of the Canadian MS CLinics Network on: the use of disease modifying agents in multiple sclerosis.

Oger J, Freedman M.

Can J Neurol Sci. 1999 Nov;26(4):274-5. Review. English, French. No abstract available.

PMID:
10610197
[PubMed - indexed for MEDLINE]
7.

Interferon beta and glatiramer acetate therapy.

McGraw CA, Lublin FD.

Neurotherapeutics. 2013 Jan;10(1):2-18. doi: 10.1007/s13311-012-0163-4. Review.

PMID:
23264098
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Use of interferon-beta in the treatment of multiple sclerosis.

Derwenskus J, Lublin FD.

Adv Neurol. 2006;98:257-71. Review. No abstract available.

PMID:
16400838
[PubMed - indexed for MEDLINE]
9.

[Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].

Federal service on surveillance in healthcare and social development (Roszdravnadzor).

Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(2 Pt 2):93-8. Russian. No abstract available.

PMID:
21916163
[PubMed - indexed for MEDLINE]
10.

Glatiramer and suspected multiple sclerosis. No proven advantage.

[No authors listed]

Prescrire Int. 2010 Aug;19(108):160. No abstract available.

PMID:
20941852
[PubMed - indexed for MEDLINE]
11.

Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis.

Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S.

Adv Ther. 2011 Jan;28(1):51-61. doi: 10.1007/s12325-010-0093-7. Epub 2010 Dec 6.

PMID:
21153000
[PubMed - indexed for MEDLINE]
12.

Concomitant therapy for multiple sclerosis.

Stuart WH, Vermersch P.

Neurology. 2004 Dec 14;63(11 Suppl 5):S28-34. Review.

PMID:
15596733
[PubMed - indexed for MEDLINE]
13.

[Additional indicators of the assessment of efficacy of disease modifying drugs (preliminary results)].

Iakushina TI, LizhdvoÄ­ VIu, Vasilenko IA, Andriukhina OM, Kotov SV.

Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(2 Pt 2):61-5. Russian.

PMID:
23528596
[PubMed - indexed for MEDLINE]
14.

The use of interferon Beta and glatiramer acetate in multiple sclerosis.

Goodin DS.

Semin Neurol. 2013 Feb;33(1):13-25. doi: 10.1055/s-0033-1343792. Epub 2013 May 25. Review.

PMID:
23709209
[PubMed - indexed for MEDLINE]
15.

Pharmacologic management of multiple sclerosis.

Blasier MG.

Urol Nurs. 2008 Jun;28(3):217-9. No abstract available.

PMID:
18605517
[PubMed - indexed for MEDLINE]
16.

Neutralising antibodies against interferon beta in multiple sclerosis.

Mikol D.

Lancet. 2004 Jan 10;363(9403):167-8; author reply 168-9. No abstract available.

PMID:
14726179
[PubMed - indexed for MEDLINE]
17.

Interferon beta in multiple sclerosis: how much BENEFIT?

Pittock SJ.

Lancet. 2007 Aug 4;370(9585):363-4. No abstract available. Erratum in: Lancet. 2007 Oct 6;370(9594):1208.

PMID:
17678997
[PubMed - indexed for MEDLINE]
18.

[The technology of treatment of multiple sclerosis with long-term immunomodulating drugs (disease modifying drugs--DMD)--beta-interferons and glatiramer-acetate].

Federal service on surveillance in healthcare and social development (Roszdravnadzor).

Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(2 Pt 2):86-92. Russian.

PMID:
21916162
[PubMed - indexed for MEDLINE]
19.

Approaches to neuroprotective strategies in multiple sclerosis.

Tselis A, Khan OA, Lisak RP.

Expert Opin Pharmacother. 2010 Dec;11(17):2869-78. doi: 10.1517/14656566.2010.508070. Epub 2010 Aug 5. Review.

PMID:
20687779
[PubMed - indexed for MEDLINE]
20.

Corticosteroids in combination therapy for multiple sclerosis.

Cohen JA.

Lancet Neurol. 2009 Jun;8(6):502-3. doi: 10.1016/S1474-4422(09)70089-4. Epub 2009 May 4. No abstract available.

PMID:
19409855
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk